← Human Trials & Peer-Reviewed Studies
Semaglutide (Wegovy) Treatment for Trichotillomania
Plain-language guide to NCT07282769: phase 2 interventional trial of Semaglutide, 10 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07282769
- Phase
- phase 2
- Status
- not yet recruiting
- Start
- 2026-06
- Completion (planned or actual)
- 2027-02
- Participants
- 10 (estimated)
- Design
- na, open label (everyone knows who gets what), treatment
- Conditions studied
- Trichotillomania (Hair-Pulling Disorder); Trichotillomania; Hair Pulling Disorder; Hair Pulling; Hair-Pulling Disorder
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered phase 2 trial tested Semaglutide.
It had 1 arm (groups): Semaglutide (Wegovy) (experimental).
Participants will receive semaglutide (Wegovy) weekly for 8 weeks.
The registry classes the interventions as drug.
More on the Plan
Participants with trichotillomania will be started and continued on medication during an 8-week treatment phase.
Who Took Part
The registry lists 10 planned participants were the target.
It was open to people of any sex aged from 18 years up to 75 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Men and women age 18-75;. Diagnosis of current trichotillomania based on DSM-5 criteria and confirmed using the clinician-administered MIDI (13);. Women of childbearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;. Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence.
The full record lists 5 inclusion and 19 exclusion criteria; among the exclusions: infrequent pulling (i.e. less than daily) or automatic pulling (i.e. no urges to pull);; history of seizures;; myocardial infarction within 6 months;.
How the Study Was Run
It was run as a single-group and open-label study.
Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2026-06 with completion listed for 2027-02.
Its stated primary purpose is treatment.
What Was Measured
Researchers chose this as the main measure: NIMH Trichotillomania Severity Scale.
It also tracked 2 secondary outcomes, for example Massachusetts General Hospital Hair Pulling Scale.
What This Means in Plain Language
Put simply, this is a phase 2 trial of Semaglutide in 10 people.
Its size is small, so on its own it can only give an early look.
Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.